Lung Cancer

BLU-945 alone or in combination with osimertinib demonstrated early signals of clinical activity and was well tolerated in heavily pretreated patients with EGFR-mutant non–small cell lung cancer.

The FDA has granted breakthrough therapy designation to zenocutuzumab for use as a potential therapeutic option in patients with advanced unresectable or metastatic, NRG1 fusion–positive non–small cell lung cancer following progression with prior systemic therapy.

A brief discussion on key barriers to molecular testing in non–small cell lung cancer and how multidisciplinary care plays a role in addressing these hurdles.

George Simon, MD, FACP, FCCP, discusses findings from an FDA pooled analysis of PD-1/PD-L1 inhibitors with or without chemotherapy in patients with non–small cell lung cancer.

Expert perspectives on selecting between neoadjuvant and perioperative chemoimmunotherapy in patients with resectable early-stage NSCLC.

Sandip Patel, MD, reviews the study design, results and clinical implications of the KEYNOTE-671 and NEOTORCH studies that evaluated perioperative chemoimmunotherapy in the treatment of early-stage NSCLC.

Datopotamab deruxtecan provided a statistically significant improvement in progression-free survival compared with standard-of-care docetaxel in patients with locally advanced or metastatic non–small cell lung cancer who received at least 1 prior line of therapy.

Adagrasib has demonstrated intracranial activity among patients with KRAS G12C–mutated non–small cell lung cancer with untreated central nervous system metastases.

Jorge Nieva, MD, and Ashish Saxena, MD, PhD, discuss the possibility of expanding the use of supportive care regimens to reduce the effects of myelosuppression in patients with SCLC.

A panel of expert oncologists present the case of a 68-year-old man with newly diagnosed, extensive stage small-cell lung cancer and brain metastases, who is treated with carboplatin, etoposide, and durvalumab, and provide their initial impressions.

Faculty discuss the evolving role of molecular markers in small-cell lung cancer and the need for future research to identify improved biomarkers for targeted treatment options.

ONC-392/BNT316 demonstrated early signs of antitumor activity and manageable safety in patients with metastatic, PD-(L)1–resistant non–small cell lung cancer.

Andreas Saltos, MD, discusses final results from a phase 2 trial of first-line pembrolizumab plus vorinostat in patients with metastatic non–small cell lung cancer.

Lova L. Sun, MD, MSCE, discusses the association between duration of immunotherapy and overall survival in patients with advanced non–small-cell lung cancer.

Alexander I. Spira, MD, PhD, FACP, discusses the ongoing phase 3 PACIFIC-8 trial of durvalumab in combination with domvanalimab following concurrent chemoradiotherapy in patients with unresectable stage III non–small cell lung cancer.

Expert oncologists reflect on the current state of molecular testing in patients with non–small cell lung cancer and how it has impacted treatment pathways.

James Chih-Hsin Yang, MD, discusses the investigation of pembrolizumab plus pemetrexed and platinum-based chemotherapy in patients with TKI-resistant, EGFR-mutant, metastatic nonsquamous non–small cell lung cancer.

Bruna Pellini, MD, discusses the use of circulating tumor DNA monitoring to inform maintenance outcomes in patients with advanced non–small cell lung cancer treated with induction therapy with atezolizumab, carboplatin, and nab-paclitaxel.

David Harpole, MD, discusses study design, results and clinical implications of the AEGEAN study of perioperative immunotherapy (neoadjuvant durvalumab plus chemotherapy followed by adjuvant durvalumab in the treatment of early-stage NSCLC

Overview and clinical implications of the CheckMate-816 study of neoadjuvant nivolumab plus platinum chemotherapy versus chemotherapy alone in early-stage NSCLC.

The European Commission has approved nivolumab in combination with platinum-based chemotherapy for the neoadjuvant treatment of patients with resectable non–small cell lung cancer at high risk of recurrence with tumor cell PD-L1 expression of at least 1%.

Vincent K. Lam, MD, discusses findings from a study profiling the tumor immune microenvironment in patients with ALK fusion–positive lung cancer and potential future directions for this research.

The FDA has granted fast track designation to the combination of quaratusugene ozeplasmid and atezolizumab as maintenance therapy in patients with extensive-stage small cell lung cancer whose disease did not progress after receiving initial standard treatment with atezolizumab and chemotherapy.

The National Medical Products Administration in China has accepted for review a new drug application seeking the approval of repotrectinib for use in adult patients with locally advanced or metastatic ROS1-positive non–small cell lung cancer.

The combination of galinpepimut-S and nivolumab provided positive survival outcomes with an acceptable safety profile in patients with malignant pleural mesothelioma who were refractory to or relapsed after at least 1 line of standard treatment.